Journal of Clinical Oncology
Articles in this Issue
Incidence and predictors of delayed hematologic engraftment after autologous stem cell transplantation and early post-transplant complications: A retrospective study.
e19103 Background: Delayed hematologic engraftment after autologous stem cell transplantation (ASCT) may prolong cytopenia...
Exploratory study of <i>TP53</i> mutations in circulating tumor DNA as prognostic and longitudinal monitoring biomarkers for relapsed ovarian carcinoma patients.
e17568 Background: This study aims to investigate the prognostic and recurrence monitoring applications of...
Bridging the access gap: First-line blinatumumab for KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) in a public health system.
e23441 Background: Infant acute lymphoblastic leukemia (ALL) accounts for approximately 4% of pediatric ALL and remains as...
Neoadjuvant chemotherapy and individualized de-escalation surgery for fertility preservation in stage IB1-IIA2 cervical cancer: A multicenter prospective study (FIND study).
5533 Background: Radical trachelectomy (RT) has long been the standard fertility-sparing surgery (FSS) for early-stage cer...
Nanochemo-immunotherapy of ER-positive metastatic breast cancer (MBC) with PEG-liposomal doxorubicin (PLD) and pembrolizumab (PEM).
1060 Background: PLD is a nanomedicine containing doxorubicin, a potent immunogenic cell death inducer. Based on the pharm...
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.
TPS7102 Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL), typically presenting...
A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma (ACC) or metastatic castration-resistant prostate cancer (mCRPC).
TPS3179 Background: ACC and mCRPC are difficult-to-treat malignancies. mCRPC typically progresses despite androgen depriva...
Risk factors for relapse in patients with stage I testicular seminoma.
e17011 Background: The relapse rate for patients with clinical stage I seminoma is approximately 20% and surveillance is s...
A comparative socio-ecological analysis of psychosocial barriers to breast and cervical cancer screening across three Nigerian states: Significance of location.
e13624 Background: Community-based screening programs and the availability of community cancer care facilities are vital t...
The cost of cancer care in Singapore: A population-based analysis of healthcare expenditures and survivorship.
e23397 Background: Cancer is the leading cause of death in Singapore and advances in diagnostics and therapeutics have inc...
Impact of MASLD in-hospital mortality in patients with cholangiocarcinoma: A nationwide analysis.
e16217 Background: Cholangiocarcinoma is an aggressive hepatobiliary malignancy frequently requiring hospitalization due t...
Immunotherapy access disruptions in Mexico: Real-world delivery irregularities at a public cancer referral center.
1511 Background: Immunotherapy improves outcomes in selected cancers, but access in middle-income countries may be limited...
Immune infiltration features relative to cancer cell clumps as predictors of survival in triple-negative breast cancer.
1134 Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. While immune infiltrat...
Integrated transcriptomic profiling and explainable machine learning to reveal functional reprogramming and biomarker candidates in pancreatic ductal adenocarcinoma.
e16002 Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive and lethal malignancies of the dig...
First-in-human study of SYS6043, a novel B7-H3–targeting antibody-drug conjugate, in patients with advanced pan-tumor malignancies.
3002 Background: B7-H3, a tumor-associated immune checkpoint, is broadly overexpressed in multiple solid tumors and associ...
Sepsis-related 30- and 90-day readmissions among patients with pancreatic cancer: A nationwide readmissions database analysis.
e23240 Background: Pancreatic cancer is associated with high morbidity, frequent hospitalizations, and limited physiologic...
PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with <i>HER2</i> -mutant advanced NSCLC.
8616 Background: Zongertinib is an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing wil...
QL1706 (PD-1/CTLA-4 bispecific antibody) plus bevacizumab specific for patients with hepatocellular carcinoma combined with lung metastasis: A secondary analysis of a prospective, single-arm, phase Ib/II study.
4114 Background: Hepatocellular carcinoma (HCC) with lung metastasis carries a dismal prognosis, and effective systemic tr...
Genomic determinants of cisplatin resistance in germ cell tumors.
5027 Background: Cisplatin-based chemotherapy achieves complete remission in 70-80% of patients with germ cell tumors (GCT...
Reducing avoidable observation stays in cancer patients requiring procedural interventions through standardized ED pathways.
e23289 Background: Patients with cancer frequently present to the emergency department (ED) with symptomatic malignant ple...
Overall survival by genomic profile in HER2-positive (HER2+) metastatic breast cancer (mBC): A large US clinico-genomic database study.
1045 Background: Over the past few years, the landscape of treatment for HER2+ breast cancer has evolved significantly. Mu...
Impact of malnutrition and morbid obesity on inpatient mortality among patients with hematologic malignancies: A National Inpatient Sample analysis.
e23091 Background: Nutrition is a critical yet frequently under-recognized determinant of clinical outcomes in patients wi...
Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines (TMGs) on ILD/pneumonitis outcomes: A retrospective analysis of patients (pts) treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06 (DB-06).
1063 Background: DB-06 (NCT04494425) showed a progression-free survival benefit with T-DXd vs physician’s choice of chemot...
TP53 co-mutations and survival outcomes in patients (pts) with NSCLC bearing uncommon EGFR alterations.
e20721 Background: Pts with NSCLC bearing uncommon EGFR alterations experienced inferior survival with tyrosine kinase inh...
Quality-driven medical oversight in global oncology trials: Standardizing immune-related AE management to enhance patient safety.
e23311 Background: Immune-based therapies have transformed the treatment landscape across multiple malignancies; however,...